Remedium Lifecare Ltd.
Remedium Lifecare Ltd. Fundamental Analysis
Remedium Lifecare Ltd. (REMLIFE.BO) shows moderate financial fundamentals with a PE ratio of 6.11, profit margin of 2.28%, and ROE of 20.08%. The company generates $5.4B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 33.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze REMLIFE.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakREMLIFE.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentREMLIFE.BO trades at attractive valuation levels.
Growth Score
ModerateREMLIFE.BO shows steady but slowing expansion.
Financial Health Score
ModerateREMLIFE.BO shows balanced financial health with some risks.
Profitability Score
WeakREMLIFE.BO struggles to sustain strong margins.
Key Financial Metrics
Is REMLIFE.BO Expensive or Cheap?
P/E Ratio
REMLIFE.BO trades at 6.11 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, REMLIFE.BO's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values Remedium Lifecare Ltd. at 0.70 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -69.10 times EBITDA. This is generally considered low.
How Well Does REMLIFE.BO Make Money?
Net Profit Margin
For every $100 in sales, Remedium Lifecare Ltd. keeps $2.28 as profit after all expenses.
Operating Margin
Core operations generate 0.62 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.08 in profit for every $100 of shareholder equity.
ROA
Remedium Lifecare Ltd. generates $0.74 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Remedium Lifecare Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Remedium Lifecare Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
REMLIFE.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
6.11
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.70
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.14
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
10.34
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.07
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.007
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How REMLIFE.BO Stacks Against Its Sector Peers
| Metric | REMLIFE.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 6.11 | 24.97 | Better (Cheaper) |
| ROE | 20.08% | 1167.00% | Weak |
| Net Margin | 2.28% | 673.00% | Weak |
| Debt/Equity | 10.34 | 0.66 | Weak (High Leverage) |
| Current Ratio | 1.07 | 4.01 | Neutral |
| ROA | 0.74% | -8477.00% (disorted) | Weak |
REMLIFE.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Remedium Lifecare Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary
EPS CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary
FCF CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary